Irbesartán Almus (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal glands, preventing vasoconstriction and aldosterone release. This results in vessel relaxation, reduced sodium‑water retention, and lower blood pressure, while also decreasing stress on the kidneys.

The appropriate dose of Irbesartán Almus is determined by the prescribing clinician based on the patient’s blood pressure, kidney function, and overall health status. Dosage adjustments are made according to clinical response and tolerability.

Safety of irbesartan in pregnancy has not been established, and it is generally avoided because of potential fetal risk. Limited data exist for breastfeeding; therefore, use should be considered only if the potential benefit outweighs the possible risk to the infant.

To place an order, submit an enquiry on the Irbesartán Almus product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly on vascular smooth‑muscle calcium channels, providing a complementary mechanism.

Irbesartán Almus should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in humid or excessively hot environments.

Irbesartán Almus is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious risks include angioedema, which can affect breathing, acute renal impairment, and significant hyperkalemia. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing, as well as sudden changes in kidney function or elevated potassium levels.

Irbesartán Almus is contraindicated in patients with known hypersensitivity to irbesartan or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment and in pregnant women, as the safety profile in these groups is not established.